Skip to content
ZenBodyLove

Other longevity agents (senolytics, GLP-1, clocks, resveratrol)

Four agents and tools marketed for longevity rest on thin human evidence. Senolytics such as dasatinib plus quercetin have been tested only in a handful of small early-phase studies, and a 2026 systematic review calls them investigational. GLP-1 receptor agonists are prescription medicines whose cardiovascular and weight outcomes come from trials in people with obesity or diabetes; slowing of ageing has been shown only in mice. Epigenetic age clocks are not yet validated as proof that an intervention slows ageing, and human trials of resveratrol have not reproduced the effects seen in animals. No claim here reaches moderate or high certainty because no randomised trial has measured ageing or longevity outcomes for any of these agents in healthy people.

  • Longevity

Evidence retrieved up to

What the research shows

Senolytic drugs and compounds such as dasatinib plus quercetin have been tested in humans only in a handful of small, short, mostly uncontrolled early-phase studies; these show feasibility and some changes in selected functional measures and biomarkers, but no evidence that they slow ageing or improve longer-term health outcomes, and they remain investigational.

Very low certaintyThis is uncertain; treat it as a lead, not a finding.
Take care: see the safety noteUnclear

Who this is about

adults with age-related conditions taking part in early-phase senolytic studies

Practical note

Graded very-low: a 2026 systematic review found six completed human studies, mostly small pilots or non-randomised designs (risk of bias, imprecision), in people with specific conditions rather than healthy older adults (indirectness), with surrogate and functional rather than clinical outcomes. In the first-in-human pilot of dasatinib plus quercetin (14 people with idiopathic pulmonary fibrosis) walking and chair-stand measures improved without a control group, while lung function and a frailty index did not change.

Vegan note

Quercetin and fisetin are flavonoids found in plant foods; their presence in a plant-based diet is not evidence of any senolytic effect at dietary intakes.

Safety note

Adverse events in the small studies were mostly mild, but small samples and short follow-up mean uncommon and long-term risks are unknown. These combinations have been used only within supervised clinical research.

Sources

GLP-1 receptor agonists such as semaglutide are prescription medicines whose cardiovascular and weight outcomes come from trials in people with obesity, overweight with existing cardiovascular disease, or type 2 diabetes; slowing of ageing and longer lifespan have been shown only in mice, and no trial has shown that they slow ageing in healthy people.

Very low certaintyThis is uncertain; treat it as a lead, not a finding.
Caution: see the safety noteUnclear

Who this is about

healthy adults considering GLP-1 receptor agonists for longevity

Practical note

Graded very-low for an ageing benefit in healthy people: the human outcome trials enrolled people with obesity or diabetes (serious indirectness), the lifespan evidence is a single study in female mice, and a 2026 review notes that definitive trials with ageing endpoints have not been done.

Vegan note

Not assessed: the formulations were not checked for animal-derived ingredients.

Safety note

These are prescription-only medicines with their own risks and eligibility criteria. In the large SELECT trial about twice as many participants stopped semaglutide as stopped placebo because of adverse events (16.6 versus 8.2 percent). Decisions about these medicines belong with the prescribing clinician.

Sources

Epigenetic age clocks and other biomarkers of ageing are not yet validated as treatment targets or as proof that an intervention slows ageing in humans; experts report limited consensus on which biomarkers to use in intervention studies, and the link between clock changes and later health is still uncertain.

Low certaintyFurther research is likely to change this.
Take care: see the safety noteUnclear

Who this is about

adults in studies of interventions marketed to slow ageing

Practical note

Graded low: the evidence is expert consensus, surveys and commentary rather than trials that tested whether clock changes after an intervention predict later health; several authors declare patents or company roles in clocks (possible conflicts of interest).

Safety note

A change in a commercial biological-age test result is not evidence of better health and is not a reason to start, stop or change a medicine or supplement.

Sources

Human trials of resveratrol supplements have not reproduced the benefits seen in animal studies: pooled trials found no significant effect on cognition, mood, blood pressure, C-reactive protein, blood lipids or glucose, and there is no human evidence that resveratrol slows ageing.

Low certaintyFurther research is likely to change this.
No known concerns at usual amountsNo clear effect

Who this is about

adults in randomised trials of resveratrol supplements

Practical note

Graded low: meta-analyses of randomised trials, downgraded for small, short and heterogeneous trials (imprecision, inconsistency) and because no trial measured ageing or lifespan outcomes (indirectness). A 2024 descriptive review of almost 200 studies reported reductions in some inflammatory markers, which conflicts with the 2015 meta-analysis finding for C-reactive protein.

Vegan note

Resveratrol is a plant compound found in grapes and some other plants; the null trial results concern supplements, not whole plant foods.

Safety note

Resveratrol supplements were generally well tolerated in short trials; long-term safety in healthy people has not been established.

Sources